We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.
Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is included in the company’s total 165 million outstanding...
Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities.Tevogen Bio plans to...
WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of...
WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf...
Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment...
Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services at Verita CSG, Inc., a...
Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN) Chief Information Officer and Head of company’s Artificial Intelligence Initiative, Tevogen.ai, Mittul Mehta, has taken strides to emphasize the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.22 | -56.4814814815 | 2.16 | 2.16 | 0.803 | 212447 | 1.39623826 | CS |
4 | -2.85 | -75.1978891821 | 3.79 | 4.78 | 0.803 | 1172517 | 3.22415902 | CS |
12 | -3.16 | -77.0731707317 | 4.1 | 21.09 | 0.803 | 468745 | 3.37122917 | CS |
26 | -3.16 | -77.0731707317 | 4.1 | 21.09 | 0.803 | 468745 | 3.37122917 | CS |
52 | -3.16 | -77.0731707317 | 4.1 | 21.09 | 0.803 | 468745 | 3.37122917 | CS |
156 | -3.16 | -77.0731707317 | 4.1 | 21.09 | 0.803 | 468745 | 3.37122917 | CS |
260 | -3.16 | -77.0731707317 | 4.1 | 21.09 | 0.803 | 468745 | 3.37122917 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions